Palisade Bio Inc

0.00 (-0.95%)
Earnings Announcements

Palisade Bio Says Cash And Cash Equivalents As Of June 30, 2021 Was $12.7 Mln, While Outstanding Debt Was $1.1 Mln

Published: 08/24/2021 12:33 GMT
Palisade Bio Inc (PALI) - Palisade Bio Reports Second Quarter Financial Results and Provides Business Update.
Palisade Bio Inc - Cash and Cash Equivalents As of June 30, 2021 Was $12.7 Million, While Outstanding Debt Was $1.1 Million.
Palisade Bio Inc Qtrly Loss per Share $4.10.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.